The company said the FDA had accepted its application for accelerated approval of Tazverik in relapsed/refractory follicular lymphoma. The drug won accelerated approval last month for epithelioid sarcoma.
The agency gave accelerated approval to Tazverik in epithelioid sarcoma, a rare but serious connective tissue cancer. The company is also seeking approval for the drug, an EZH2 inhibitor, for the blood cancer follicular lymphoma.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.